Twist Bioscience Corporation Contract Liability (Deferred Revenue)
Twist Bioscience Corporation (TWST) had Contract Liability (Deferred Revenue) of $6.47 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Deferred Revenue, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-03
- 2026-06-30: Contract with Customer, Liability, Current $6.47M.
- 2025-09-30: Contract with Customer, Liability, Current $6.88M.
- 2021-03-31: Contract with Customer, Liability, Current $600.00K.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2026-06-30 | $6.47M 10-Q · filed 2026-08-03 |
| 2025-09-30 | $6.88M 10-Q · filed 2026-08-03 |
| 2021-03-31 | $600.00K 10-Q · filed 2021-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |